KBC Group
BBIO icon

KBC Group’s BridgeBio Pharma BBIO Stock Holding History

KBC Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Buy
4,743
+548
+13% +$39.7K ﹤0.01% 840
2025
Q4 		$321K Hold
4,195
– – ﹤0.01% 781
2025
Q3 		$218K Hold
4,195
– – ﹤0.01% 871
2025
Q2 		$181K Sell
4,195
-1,905
-31% -$69.3K ﹤0.01% 905
2025
Q1 		$211K Buy
6,100
+153
+3% +$5.16K ﹤0.01% 1038
2024
Q4 		$163K Buy
5,947
+2,456
+70% +$63.5K ﹤0.01% 1247
2024
Q3 		$89K Buy
3,491
+649
+23% +$17K ﹤0.01% 1359
2024
Q2 		$72K Hold
2,842
– – ﹤0.01% 1386
2024
Q1 		$88K Buy
2,842
+887
+45% +$30.2K ﹤0.01% 1190
2023
Q4 		$79K Sell
1,955
-256
-12% -$7.69K ﹤0.01% 1209
2023
Q3 		$58K Buy
+2,211
New +$62.7K ﹤0.01% 1322

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KBC Group's BBIO Position: Q1 2026 in Review

KBC Group increased its BridgeBio Pharma (BBIO) stake by 13% in Q1 2026, buying an estimated $39.7K and bringing the position to 4,743 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

KBC Group first reported a position in BBIO in Q3 2023 and has held it in 11 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • KBC Group held 4,743 shares of BridgeBio Pharma worth $352K as of Q1 2026.
  • KBC Group bought 548 BridgeBio Pharma shares in Q1 2026, an estimated $39.7K.
  • BridgeBio Pharma made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #840 holding.
  • KBC Group first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 11 quarters since.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.